Dr Kenneth Oguejiofor
MBBS, MRes, PhD, MRCP, FRCR, Consultant Clinical Oncologist
Languages spoken
English
Overview
Specialises in
Treatments
Dr Oguejiofor is a Consultant Clinical Oncologist at University Hospital Southampton, specialising in genitourinary and head and neck cancers. His clinical expertise includes advanced radiotherapy techniques, including volumetric modulated arc therapy (VMAT) and stereotactic ablative radiotherapy (SABR), alongside systemic therapies for prostate cancer and immunotherapy for head and neck cancers.
He qualified at the University of Jos in Nigeria before completing an MRes and PhD at the University of Manchester, where his research at The Christie Hospital focused on HPV-related oropharyngeal cancer and tumour immunology. He trained in clinical oncology across Southampton, Portsmouth, and Poole, and completed a proton beam therapy fellowship at The Christie Hospital. He holds MRCP and FRCR qualifications and has over 15 peer-reviewed publications in high-impact oncology journals.
I was drawn to oncology by the unique combination of cutting-edge technology and deep human connection it demands. Cancer treatment is one of the few areas in medicine where you build a relationship with a patient over months or years, guiding them through some of the most difficult moments of their life while applying the most advanced radiotherapy and systemic treatments available. I chose to specialise in genitourinary and head and neck cancers because they offer the opportunity to combine precision radiotherapy techniques with the rapidly evolving fields of immunotherapy and targeted therapy.
Career positions
Consultant Clinical Oncologist at GenesisCare
Other practising or consulting locations
University Hospitals Southampton / Salisbury District Hospital
Clinical & research interests
- HPV-related oropharyngeal cancers and the role of tumour-infiltrating lymphocytes as prognostic biomarkers
- Radiosensitivity gene signatures in cancer
- The spatial relationship between immune cells and PD-L1 expression in head and neck squamous cell carcinoma
- Integration of immunotherapy with radiotherapy in GU malignancies
- Proton beam therapy, advanced radiotherapy techniques including VMAT and SABR, systemic therapies for genitourinary cancers including ARPIs and chemotherapy combinations, targeted therapy and immunotherapy for head and neck cancers
Professional memberships
- Fellow, Royal College of Radiologists (FRCR)
- Member, Royal College of Physicians (MRCP)
- General Medical Council (GMC Registration No. 7143445)
Publications & affiliations
1. Oguejiofor K, Ramkumar S, Nabi AA, et al. Comparing Survival Outcomes and Recurrence Patterns in Oral Cavity Squamous Cell Carcinoma (OCSCC) Patients Treated With Curative Intent Either With Adjuvant or Definitive (Chemo)radiotherapy. Clin Oncol (R Coll Radiol). 2025;43:103855. doi:10.1016/j.clon.2025.103855
2. Tsakiroglou AM, Fergie M, Oguejiofor K, et al. Spatial proximity between T and PD-L1 expressing cells as a prognostic biomarker for oropharyngeal squamous cell carcinoma. Br J Cancer. 2020;122(4):539-544. doi:10.1038/s41416-019-0634-z
3. Oguejiofor K, Galletta-Williams H, Dovedi SJ, Roberts DL, Stern PL, West CM. Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. Oncotarget. 2017;8(9):14416-14427. doi:10.18632/oncotarget.14796
4. Oguejiofor K, Hall J, Slater C, et al. Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma. Br J Cancer. 2015;113(6):886-893. doi:10.1038/bjc.2015.277
5. Oguejiofor K, Hall JS, Mani N, et al. The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma. Clin Oncol (R Coll Radiol). 2013;25(11):630-638. doi:10.1016/j.clon.2013.07.003